Rituximab efficiently depletes B cells in lung tumors and normal lung tissue

Rituximab is a monoclonal antibody that targets the CD20 B-cell-specific antigen and is widely used as therapy for B-cell lymphoma. Since rituximab depletes both malignant and normal B cells, it is increasingly being used to treat various conditions in which normal B cells have a pathogenic role, su...

Descripción completa

Detalles Bibliográficos
Autores principales: Joly-Battaglini, Albane, Hammarström, Clara, Stankovic, Branislava, Aamodt, Henrik, Stjärne, Johan, Brustugun, Odd Terje, Helland, Åslaug, Øynebråten, Inger, Corthay, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813631/
https://www.ncbi.nlm.nih.gov/pubmed/27081474
http://dx.doi.org/10.12688/f1000research.7599.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813631/
https://www.ncbi.nlm.nih.gov/pubmed/27081474
http://dx.doi.org/10.12688/f1000research.7599.1

Ejemplares similares